Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (71-80 of 204) with videos related to

Pageof 21
Sort By:
Expert Review of Anti-Infective Therapy|May 31, 2019
Quantitative assessment of the activity of antituberculosis drugs and regimensMaxwell T Chirehwa, Gustavo E Velásquez, Tawanda Gumbo, et al.
The Lancet. Respiratory Medicine|March 30, 2018
Pan-tuberculosis regimens: an argument againstKeertan Dheda, Tawanda Gumbo, Christoph Lange, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2010
In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosisPrakash M Jeena, William R Bishai, Jotam G Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugsTawanda Gumbo, Chandima S W Siyambalapitiyage Dona, Claudia Meek, et al.
Antimicrobial Agents and Chemotherapy|August 6, 2014
Redefining multidrug-resistant tuberculosis based on clinical response to combination therapyTawanda Gumbo, Jotam G Pasipanodya, Peter Wash, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and ConfirmTawanda Gumbo, Jotam G Pasipanodya, Eric Nuermberger, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2017
Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex diseaseJotam G Pasipanodya, Deborah Ogbonna, Devyani Deshpande, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Systematic Analysis of Hollow Fiber Model of Tuberculosis ExperimentsJotam G Pasipanodya, Eric Nuermberger, Klaus Romero, et al.
The Journal of Infectious Diseases|May 27, 2015
Nonclinical models for antituberculosis drug development: a landscape analysisTawanda Gumbo, Anne J Lenaerts, Debra Hanna, et al.
The Journal of Infectious Diseases|October 25, 2011
Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityShashikant Srivastava, Jotam G Pasipanodya, Claudia Meek, et al.
Pageof 21

Showing results (71-80 of 204) with videos related to

Sort By:
Pageof 21
Expert Review of Anti-Infective Therapy|May 31, 2019
Quantitative assessment of the activity of antituberculosis drugs and regimensMaxwell T Chirehwa, Gustavo E Velásquez, Tawanda Gumbo, et al.
The Lancet. Respiratory Medicine|March 30, 2018
Pan-tuberculosis regimens: an argument againstKeertan Dheda, Tawanda Gumbo, Christoph Lange, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2010
In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosisPrakash M Jeena, William R Bishai, Jotam G Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugsTawanda Gumbo, Chandima S W Siyambalapitiyage Dona, Claudia Meek, et al.
Antimicrobial Agents and Chemotherapy|August 6, 2014
Redefining multidrug-resistant tuberculosis based on clinical response to combination therapyTawanda Gumbo, Jotam G Pasipanodya, Peter Wash, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and ConfirmTawanda Gumbo, Jotam G Pasipanodya, Eric Nuermberger, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2017
Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex diseaseJotam G Pasipanodya, Deborah Ogbonna, Devyani Deshpande, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Systematic Analysis of Hollow Fiber Model of Tuberculosis ExperimentsJotam G Pasipanodya, Eric Nuermberger, Klaus Romero, et al.
The Journal of Infectious Diseases|May 27, 2015
Nonclinical models for antituberculosis drug development: a landscape analysisTawanda Gumbo, Anne J Lenaerts, Debra Hanna, et al.
The Journal of Infectious Diseases|October 25, 2011
Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variabilityShashikant Srivastava, Jotam G Pasipanodya, Claudia Meek, et al.
Pageof 21